samuraciclib   Click here for help

GtoPdb Ligand ID: 9903

Synonyms: CT7001 [2] | ICEC-0942 | ICEC0942 | PPDA-001 [1]
PDB Ligand
Compound class: Synthetic organic
Comment: Samuraciclib (ICEC0942, a.k.a. CT7001) is an orally available, non-covalent, selective inhibitor of cyclin dependent kinase 7 (CDK7) that was developed as a new transcription-targeting approach for potential cancer therapy [2]. It was developed by the same group who identified BS-181. The chemical structure is claimed in patent US20160362410A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 86.51
Molecular weight 394.25
XLogP 3.9
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC1CNCCC1CNc1cc(NCc2ccccc2)n2c(n1)c(cn2)C(C)C
Isomeric SMILES O[C@H]1CNCC[C@@H]1CNc1cc(NCc2ccccc2)n2c(n1)c(cn2)C(C)C
InChI InChI=1S/C22H30N6O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27)/t17-,19+/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 1/2 study designed to evaluate CT7001 as a monotherapy in advanced malignancies is underway- see NCT03363893.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03363893 Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Phase 1/Phase 2 Interventional Carrick Therapeutics Limited